Related Experiment Videos
Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer
Z Akçetin1, J Todorov, E Tüzel
1Department of Urology, Erlangen University School of Medicine, Erlangen, Germany. akcetin@aol.com
Anticancer Research
|July 22, 2005
Summary
Deep transurethral resection followed by radiochemotherapy offers a safe and curative option for stage T1 grade 3 bladder cancer. This combined therapy shows high complete response and survival rates in patients with transitional cell carcinoma.
Area of Science:
- Urology
- Oncology
- Radiation Oncology
Background:
- Stage T1 grade 3 transitional cell carcinoma (T1G3 TCC) of the bladder requires effective treatment strategies.
- Conservative therapy combining deep transurethral resection (TUR) with radiochemotherapy presents a novel approach.
Purpose of the Study:
- To evaluate the long-term outcomes of radiochemotherapy in patients diagnosed with T1G3 TCC of the bladder.
Main Methods:
- A cohort of 64 patients with T1G3 TCC underwent TUR followed by a radiochemotherapy protocol.
- The protocol included a median radiation dose of 55.8 Gy to the bladder and concurrent chemotherapy (cisplatin, carboplatin, and/or 5-fluorouracil).
- Response was assessed via repeat TUR and cystoscopies; median follow-up was 43.2 months.
Main Results:
- A complete response was observed in 90.2% of patients (55 out of 64).
- The overall progression rate was 14%, with 7 patients experiencing superficial recurrence and 8 having disease progression.
- Five-year overall survival was 76%, and disease-free survival was 93%.
Conclusions:
- Combined multimodality therapy (TUR plus radiochemotherapy) is a safe and curative option for T1G3 TCC.
- This approach is recommended as a first-line treatment for T1G3 bladder tumors by experienced multidisciplinary teams.